Population pharmacokinetics applied to optimising cisplatin doses in cancer patients;Farmacocinética poblacional de cisplatino aplicada a la personalización de su dosificación en pacientes oncológicos

Farmacia Hospitalaria

Volumn 36, Issue 5, 2012, Pages 392-402

  Ramon Lopez A ^a   Escudero Ortiz, V ^b   Carbonell, V ^c   Perez Ruixo J J ^d   Valenzuela, B ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b USP Hospital San Jaime   (Spain)

^c Centro Tecnologico Ainia   (Spain)

^d AMGEN INC   (United States)

Author keywords

Bayesian population model; Cisplatin; NONMEM; Oncology; Pharmacokinetics; Pharmacotherapy optimisation

Indexed keywords

CISPLATIN;

ACCURACY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; INTERNAL VALIDITY; POPULATION RESEARCH; PREDICTION; STEADY STATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS; SOFTWARE; YOUNG ADULT;

EID: 84866393006     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.1016/j.farma.2011.08.004     Document Type: Article

References (32)

1. H.C. Harder, and B. Rosenberg Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro Int J Cancer 6 1970 207 216
2. J.J. Roberts, and J.M. Pascoe Cross-linking of complementary strands of DNA in mammalian cells by antitumour platinum compounds Nature 235 1972 282 284
3. L.A. Zwelling, T. Anderson, and K.W. Kohn DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity Cancer Res 39 1979 365 369
4. Ficha técnica de Cisplatino Agencia Española de Medicamentos y Productos Sanitarios. Ministerio de Sanidad y Consumo.
5. S. Urien, and F. Lokiec Population pharmacokinetics of total and unbound plasma cisplatin in adult patients Br J Clin Pharmacol 57 2004 756 763
6. K. Hanada, K. Nishijima, H. Ogata, S. Atagi, and M. Kawahara Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum Jpn J Clin Oncol 31 2001 179 184
7. R. Safirstein, P. Miller, and J.B. Guttenplan Uptake and metabolism of cisplatin by rat kidney Kidney Int 25 1984 753 758
8. S. Salas, C. Mercier, J. Ciccolini, B. Pourroy, R. Fanciullino, and B. Tranchand Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma Ther Drug Monit 28 2006 532 539
9. V. Launay-Vacher, J.B. Rey, C. Isnard-Bagnis, G. Deray, M. Daouphars European Society of Clinical Pharmacy Special Interest Group on Cancer Care Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care Cancer Chemother Pharmacol 61 2008 903 909
10. T. Gelevert, J. Messerschmidt, M.T. Meinardi, F. Alt, J.A. Gietema, and J.P. Franke Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin Ther Drug Monit 23 2001 169 173
11. A. Gerl, and R. Schierl Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer Acta Oncol 39 2000 519 522
12. J.H. Hohnloser, R. Schierl, B. Hasford, and B. Emmerich Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects Eur J Med Res 1 1996 509 514
13. D.J. Stewart, R.S. Benjamin, M. Luna, L. Feun, R. Caprioli, and W. Seifert Human tissue distribution of platinum after cis-diamminedichloroplatinum Cancer Chemother Pharmacol 10 1982 51 54
14. R. Safirstein, J. Winston, D. Moel, S. Dikman, and J. Guttenplan Cisplatin nephrotoxicity: insights into mechanism Int J Androl 10 1987 325 346
15. T. Yano, Y. Itoh, M. Matsuo, T. Kawashiri, N. Egashira, and R. Oishi Involvement of both tumor necrosis factor-alpha-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin Apoptosis 12 2007 1901 1909
16. R.S. Goldstein, and G.H. Mayor Minireview. The nephrotoxicity of cisplatin Life Sci 32 1983 685 690
17. J.A. Gietema, E.G. De Vries, S. Meijer, J.J. Offerman, P.O. Mulder, and D.T. Sleijfer Absence of relation between nutritional parameters and renal function in non-seminomatous testicular cancer patients J Cancer Res Clin Oncol 114 1988 618 622
18. D.M. Hayes, E. Cvitkovic, R.B. Golbey, E. Scheiner, L. Helson, and I.H. Krakoff High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis Cancer 39 1977 1372 1381
19. R.F. Ozols Cisplatin Dose intensity Semin Oncol 16 1989 22 30
20. N. Nagai, H. Ogata, Y. Wada, D. Tsujino, K. Someya, and T. Ohno Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program J Clin Pharmacol 38 1998 1025 1034
21. B. Porta, J.J. Pérez-Ruixo, N.V. Jiménez, A. Sancho, and L.M. Pallardó Individualización posológica de ciclosporina en pacientes con trasplante renal: propuesta de un modelo farmacocinético de predicción Farm Hosp 22 1998 181 187
22. F.E. De Jongh, J. Verweij, W.J. Loos, R. De Wit, M.J. De Jonge, and A.S. Planting Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure J Clin Oncol 19 2001 3733 3739
23. E.E. Brouwers, A.D. Huitema, J.H. Beijnen, and J.H. Schellens Long-term platinum retention after treatment with cisplatin and oxaliplatin BMC Clin Pharmacol 8 2008 7
24. Beal SL, Sheiner LB, Boeckman AJ. (eds.) (1989-2006) NONMEN users guides. ICON Development Solutions, Ellicott City.
25. P.O. Gisleskog, M.O. Karlsson, and S.L. Beal Use of prior information to stabilize a population data analysis J Pharmacokinet Pharmacodyn 29 2002 473 505
26. D.D. Wang, and S. Zhang Standardized Visual Predictive Check Versus Visual Predictive Check for Model Evaluation J Clin Pharmacol 2011
27. L.B. Sheiner, and S.L. Beal Some suggestions for measuring predictive performance J Pharmacokinetic Biopharm 9 1981 503 512
28. Escudero-Ortiz V, Ramón-López A, Duart-Duart MJ, Perez-Ruixo JJ, Valenzuela, B. Farmacocinética poblacional de doxorubicina aplicada a la personalización de su dosificación en pacientes oncológicos. Farmacia Hospitalaria. Pendiente de publicación.
29. Ramón-López A, Escudero-Ortiz V, Duart-Duart MJ, Perez-Ruixo JJ, Valenzuela, B. Farmacocinética poblacional de gemcitabina aplicada a la personalización de su dosificación en pacientes oncológicos. Farmacia Hospitalaria. Pendiente de publicación.
30. G.W. Loh, L.S. Ting, and M.H. Ensom A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy Clin Pharmacokinet 46 2007 471 494
31. M.O. Karlsson, and R.M. Savic Diagnosing model diagnostics Clin Pharmacol Ther 82 2007 17 20
32. Girard P. Data Tranformation and parameter transformations in NONMEM. Population Approach Group in Europe Congress 2002. Disponible en: http://www.page-meeting.org/page/page2002/PascalGirardPage2002.pdf.